
|Articles|May 1, 2004
Tiers keep costs in tow
The jury is still out on tiered provider networks. While effectiveness is frequently a criterion for including a specific drug on a preferred drug list, thus far, quality is only playing a small part in designing provider tiers.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
2
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
3
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
4
Venclexta combination improves survival and lowers hospital stays for AML patients | ASH 2025
5





















































